Trials / Unknown
UnknownNCT04506138
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- Zhejiang Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the efficacy of Camrelizumab with neoadjuvant chemotherapy for resectable thoracic esophageal squamous cell carcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab | Camrelizumab 200mg D1, D22 |
| DRUG | Paclitaxel for Injection (Albumin Bound) | Paclitaxel for Injection (Albumin Bound) 100mg/m\^2 D1, D8, D22, D29 |
| DRUG | Carboplatin | Carboplatin AUC5 D1, D22 |
Timeline
- Start date
- 2020-08-11
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2020-08-10
- Last updated
- 2021-12-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04506138. Inclusion in this directory is not an endorsement.